Oncolytics Biotech (ONCY) Competitors

$0.81 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$0.81 0.00 (-0.31%)

As of 05/22/2026 07:58 PM Eastern

ONCY vs. LXEO, MNPR, BNTC, CCCC, and CLLS

Should you buy Oncolytics Biotech stock or one of its competitors? MarketBeat compares Oncolytics Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oncolytics Biotech include Lexeo Therapeutics (LXEO), Monopar Therapeutics (MNPR), Benitec Biopharma (BNTC), C4 Therapeutics (CCCC), and Cellectis (CLLS). These companies are all part of the "pharmaceutical products" industry.

How does Oncolytics Biotech compare to Lexeo Therapeutics?

Lexeo Therapeutics (NASDAQ:LXEO) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

In the previous week, Lexeo Therapeutics had 2 more articles in the media than Oncolytics Biotech. MarketBeat recorded 4 mentions for Lexeo Therapeutics and 2 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.00 beat Lexeo Therapeutics' score of -0.04 indicating that Oncolytics Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncolytics Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 5.3% of Lexeo Therapeutics shares are held by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lexeo Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

Lexeo Therapeutics' return on equity of -47.48% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Oncolytics Biotech	N/A	-14,442.84%	-321.54%

Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

Lexeo Therapeutics currently has a consensus price target of $18.88, indicating a potential upside of 269.37%. Oncolytics Biotech has a consensus price target of $8.50, indicating a potential upside of 950.03%. Given Oncolytics Biotech's higher possible upside, analysts plainly believe Oncolytics Biotech is more favorable than Lexeo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Lexeo Therapeutics beats Oncolytics Biotech on 8 of the 13 factors compared between the two stocks.

How does Oncolytics Biotech compare to Monopar Therapeutics?

Oncolytics Biotech (NASDAQ:ONCY) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Oncolytics Biotech has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

Oncolytics Biotech currently has a consensus target price of $8.50, indicating a potential upside of 950.03%. Monopar Therapeutics has a consensus target price of $107.00, indicating a potential upside of 69.52%. Given Oncolytics Biotech's higher probable upside, research analysts clearly believe Oncolytics Biotech is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Monopar Therapeutics had 8 more articles in the media than Oncolytics Biotech. MarketBeat recorded 10 mentions for Monopar Therapeutics and 2 mentions for Oncolytics Biotech. Monopar Therapeutics' average media sentiment score of 0.88 beat Oncolytics Biotech's score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncolytics Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Monopar Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by company insiders. Comparatively, 20.5% of Monopar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Monopar Therapeutics' return on equity of -12.84% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-14,442.84%	-321.54%
Monopar Therapeutics	N/A	-12.84%	-12.57%

Summary

Monopar Therapeutics beats Oncolytics Biotech on 10 of the 14 factors compared between the two stocks.

How does Oncolytics Biotech compare to Benitec Biopharma?

Oncolytics Biotech (NASDAQ:ONCY) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

In the previous week, Oncolytics Biotech had 2 more articles in the media than Benitec Biopharma. MarketBeat recorded 2 mentions for Oncolytics Biotech and 0 mentions for Benitec Biopharma. Oncolytics Biotech's average media sentiment score of 0.00 equaled Benitec Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Oncolytics Biotech	Neutral
Benitec Biopharma	Neutral

Oncolytics Biotech has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

Oncolytics Biotech has higher earnings, but lower revenue than Benitec Biopharma. Benitec Biopharma is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A
Benitec Biopharma	$80K	4,821.88	-$37.92M	-$1.14	N/A

Benitec Biopharma's return on equity of -34.82% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-14,442.84%	-321.54%
Benitec Biopharma	N/A	-34.82%	-34.11%

6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by insiders. Comparatively, 4.8% of Benitec Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Oncolytics Biotech presently has a consensus price target of $8.50, indicating a potential upside of 950.03%. Benitec Biopharma has a consensus price target of $27.00, indicating a potential upside of 140.43%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, research analysts clearly believe Oncolytics Biotech is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Benitec Biopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Oncolytics Biotech beats Benitec Biopharma on 8 of the 14 factors compared between the two stocks.

How does Oncolytics Biotech compare to C4 Therapeutics?

C4 Therapeutics (NASDAQ:CCCC) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

C4 Therapeutics currently has a consensus price target of $7.75, suggesting a potential upside of 117.70%. Oncolytics Biotech has a consensus price target of $8.50, suggesting a potential upside of 950.03%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Oncolytics Biotech has lower revenue, but higher earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	10.95	-$104.99M	-$1.19	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

In the previous week, Oncolytics Biotech had 1 more articles in the media than C4 Therapeutics. MarketBeat recorded 2 mentions for Oncolytics Biotech and 1 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.00 equaled Oncolytics Biotech'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncolytics Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

C4 Therapeutics has a beta of 2.77, meaning that its share price is 177% more volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

Oncolytics Biotech has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. C4 Therapeutics' return on equity of -50.68% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-297.76%	-50.68%	-33.22%
Oncolytics Biotech	N/A	-14,442.84%	-321.54%

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 5.6% of C4 Therapeutics shares are held by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Oncolytics Biotech beats C4 Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Oncolytics Biotech compare to Cellectis?

Oncolytics Biotech (NASDAQ:ONCY) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

Oncolytics Biotech has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Cellectis' return on equity of -80.66% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-14,442.84%	-321.54%
Cellectis	-89.51%	-80.66%	-20.51%

Oncolytics Biotech currently has a consensus target price of $8.50, indicating a potential upside of 950.03%. Cellectis has a consensus target price of $6.75, indicating a potential upside of 92.86%. Given Oncolytics Biotech's higher probable upside, research analysts plainly believe Oncolytics Biotech is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Oncolytics Biotech has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market. Comparatively, Cellectis has a beta of 2.94, meaning that its share price is 194% more volatile than the broader market.

Oncolytics Biotech has higher earnings, but lower revenue than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A
Cellectis	$79.59M	4.41	-$67.59M	-$0.67	N/A

In the previous week, Cellectis had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 3 mentions for Cellectis and 2 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.00 equaled Cellectis'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncolytics Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by company insiders. Comparatively, 16.4% of Cellectis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Cellectis beats Oncolytics Biotech on 9 of the 14 factors compared between the two stocks.

Get Oncolytics Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONCY vs. The Competition

Export

Metric	Oncolytics Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$96.62M	$3.37B	$6.45B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-2.61	18.74	21.22	25.65
Price / Sales	N/A	323.98	553.92	86.28
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	-20.24	7.09	10.37	7.14
Net Income	-$28.76M	$24.45M	$3.57B	$335.98M
7 Day Performance	1.17%	5.45%	6.01%	3.56%
1 Month Performance	-21.41%	2.43%	3.52%	2.54%
1 Year Performance	93.48%	62.98%	34.13%	35.05%

Oncolytics Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
ONCY Oncolytics Biotech	2.6223 of 5 stars	$0.81 flat	$8.50 +950.0%	+93.5%	$96.62M	N/A	N/A	30
LXEO Lexeo Therapeutics	1.6902 of 5 stars	$4.71 -7.5%	$18.88 +300.7%	+81.2%	$399.67M	N/A	N/A	58
MNPR Monopar Therapeutics	2.5798 of 5 stars	$56.25 -5.1%	$107.00 +90.2%	+78.1%	$397.05M	N/A	N/A	10
BNTC Benitec Biopharma	1.4537 of 5 stars	$10.89 -5.2%	$27.00 +147.9%	-14.9%	$394.73M	$80K	N/A	20
CCCC C4 Therapeutics	1.4662 of 5 stars	$3.22 -9.6%	$7.75 +140.7%	+158.0%	$393.62M	$35.95M	N/A	150

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONCY) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncolytics Biotech (ONCY) Competitors

ONCY vs. LXEO, MNPR, BNTC, CCCC, and CLLS

How does Oncolytics Biotech compare to Lexeo Therapeutics?

Summary

How does Oncolytics Biotech compare to Monopar Therapeutics?

Summary

How does Oncolytics Biotech compare to Benitec Biopharma?

Summary

How does Oncolytics Biotech compare to C4 Therapeutics?

Summary

How does Oncolytics Biotech compare to Cellectis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY vs. The Competition

Oncolytics Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncolytics Biotech (ONCY) Competitors

ONCY vs. LXEO, MNPR, BNTC, CCCC, and CLLS

How does Oncolytics Biotech compare to Lexeo Therapeutics?

Does the media favor LXEO or ONCY?

Do insiders and institutionals hold more shares of LXEO or ONCY?

Which has more volatility & risk, LXEO or ONCY?

Is LXEO or ONCY more profitable?

Which has preferable valuation & earnings, LXEO or ONCY?

Do analysts prefer LXEO or ONCY?

Summary

How does Oncolytics Biotech compare to Monopar Therapeutics?

Which has more volatility & risk, ONCY or MNPR?

Which has higher earnings and valuation, ONCY or MNPR?

Do analysts recommend ONCY or MNPR?

Does the media refer more to ONCY or MNPR?

Do insiders and institutionals believe in ONCY or MNPR?

Is ONCY or MNPR more profitable?

Summary

How does Oncolytics Biotech compare to Benitec Biopharma?

Does the media favor ONCY or BNTC?

Which has more risk & volatility, ONCY or BNTC?

Which has higher valuation and earnings, ONCY or BNTC?

Is ONCY or BNTC more profitable?

Do institutionals and insiders hold more shares of ONCY or BNTC?

Do analysts prefer ONCY or BNTC?

Summary

How does Oncolytics Biotech compare to C4 Therapeutics?

Do analysts rate CCCC or ONCY?

Which has stronger valuation and earnings, CCCC or ONCY?

Does the media prefer CCCC or ONCY?

Which has more risk & volatility, CCCC or ONCY?

Is CCCC or ONCY more profitable?

Do insiders and institutionals have more ownership in CCCC or ONCY?

Summary

How does Oncolytics Biotech compare to Cellectis?

Is ONCY or CLLS more profitable?

Do analysts prefer ONCY or CLLS?

Which has more volatility & risk, ONCY or CLLS?

Which has better valuation and earnings, ONCY or CLLS?

Does the media favor ONCY or CLLS?

Do insiders and institutionals hold more shares of ONCY or CLLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY vs. The Competition

Oncolytics Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools